NCT02364609View on ClinicalTrials.gov

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

May 1, 2020

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Afatinib Dimaleate

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Jonathan Riess

OTHER

NCT02364609 - Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib | Biotech Hunter | Biotech Hunter